Summit Therapeutics Inc. (SMMT)
| Market Cap | 19.34B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -240.76M |
| Shares Out | 742.67M |
| EPS (ttm) | -0.34 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,997,074 |
| Open | 25.66 |
| Previous Close | 25.64 |
| Day's Range | 25.07 - 26.35 |
| 52-Week Range | 2.10 - 36.91 |
| Beta | -0.95 |
| Analysts | Strong Buy |
| Price Target | 37.00 (+42.09%) |
| Earnings Date | May 1, 2025 |
About SMMT
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis, as well as in Phase III clinical trials for the treatment of non-small lung cancer. The company was founded in 2003 and is headquartered in Miami, Florida. [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for SMMT stock is "Strong Buy." The 12-month stock price forecast is $37.0, which is an increase of 42.09% from the latest price.
News
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of...
Summit Therapeutics Inc. (SMMT) Q1 2025 Earnings Call Transcript
Summit Therapeutics Inc. (SMMT) Q1 2025 Earnings Call Transcript
Final Trade: NVS, XLU and SMMT
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its operational progress for ...
Why Is Summit Therapeutics Stock Trading Higher On Monday?
Summit Therapeutics Inc. SMMT on Friday noted that Akeso, Inc. announced the Chinese Health Authorities, the National Medical Products Administration (NMPA) approved ivonescimab for a second indicati...
What's Going On With Summit Therapeutics Stock On Friday?
Summit Therapeutics Inc SMMT stock is trading lower on Friday.
Interim Overall Survival Analysis Requested from Chinese Health Authorities Shows a Clinically Meaningful, Positive Trend Favoring Ivonescimab Compared to Pembrolizumab in PD-L1 Positive Advanced NSCLC from HARMONi-2 Study Conducted by Akeso in China
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today noted that Akeso, Inc. (Akeso, HKEX Code: 9926.HK) announced that ivonescimab was app...
Summit Therapeutics to Host First Quarter 2025 Financial Results & Operational Progress Call on May 1, 2025
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host an earnings call to announce its first quarter 2025 financial results and provide...
Why Is Summit Therapeutics Stock Soaring On Wednesday?
Summit Therapeutics Inc.'s SMMT partner, Akeso, Inc., released topline data from the Phase 3 HARMONi-6/K112-306 trial on Wednesday.
Ivonescimab in Combination with Chemotherapy Achieves Statistically Significant Superiority in PFS vs. Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in HARMONi-6 Study Conducted by Akeso in China
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today noted that Akeso, Inc. (Akeso, HKEX Code: 9926.HK) announced that the Phase III clini...
Summit Therapeutics: Multibillion Dollar NSCLC Potential Faces Growing Competition
Summit Therapeutics' ivonescimab shows promising results in China, outperforming Keytruda in PD-L1 positive advanced NSCLC, with potential $10 billion peak annual revenue. Fierce competition exists in...
Analyst Initiates Coverage On 'Undervalued' Summit Therapeutics
On Friday, Cantor Fitzgerald initiated coverage on Summit Therapeutics Inc. SMMT, citing shares as 67% undervalued.
Robert LaCaze, Innovative Growth-Driver in Oncology, Joins Summit Therapeutics as Chief Commercial Officer
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Robert LaCaze has joined Summit Therapeutics as Chief Commercial Offic...
Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCs
HONG KONG , Feb. 24, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that its partner on ivonescimab, Summit Therapeutics Inc. (NASDAQ: SMMT) has entered into a c...
Summit Therapeutics: Mid-2025 NSCLC Data Could Further Entrench Ivonescimab Program
Summit Therapeutics: Mid-2025 NSCLC Data Could Further Entrench Ivonescimab Program
Summit Therapeutics Inc. (SMMT) Q4 2024 Earnings Call Transcript
Summit Therapeutics Inc. (SMMT) Q4 2024 Earnings Call Transcript
Pfizer: What The Summit Therapeutics Deal Brings
Pfizer and Summit Therapeutics announced a clinical trial collaboration that involves Pfizer's ADC pipeline and Summit's ivonescimab. Pfizer will conduct combination trials of its vedotin-based ADCs w...
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Twelve Months Ended December 31, 2024
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today reports its financial results and provides an update on operational progress for the ...
Summit Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Ivonescimab in Combination with Pfizer Antibody Drug Conjugates (ADCs)
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced a clinical trial collaboration with Pfizer Inc. (NYSE: PFE) to evaluate ivonescimab, a novel, investigational ...
Summit Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results & Operational Progress Call on February 24, 2025
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host an earnings call to announce its fourth quarter and full year 2024 financial resu...
Summit Therapeutics: Data Signals A Potential Paradigm Shift In NSCLC (Rating Upgrade)
Summit Therapeutics' stock rose 888% since September 2023, driven by positive Phase 3 data for ivonescimab showing superior PFS vs Keytruda in NSCLC. Phase 3 HARMONi-2 trial showed 11.14 vs 5.82 month...
Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 bil...
Summit Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at the 43rd Annual J.P. Morgan Heal...
Summit Therapeutics Stock Set To Soar By Mid-2025 On HARMONi Phase 3 Trial
Summit Therapeutics reached a milestone in its Phase III trial for ivonescimab, aiming to treat second-line EGFR mutated advanced NSCLC. The FDA has fast tracked the HARMONi trial. Positive Phase III...